Melanoma cell adhesion molecule as an emerging biomarker with prognostic significance in systolic heart failure. (July 2016)

• Record Type: Journal Article
• Authors: Banach, Joanna; Grochowska, Magdalena; Gackowska, Lidia; Buszko, Katarzyna; Bujak, Robert; Gilewski, Wojciech; Kubiszewska, Izabela; Wołowiec, Łukasz; Michałkiewicz, Jacek; Sinkiewicz, Władysław
• Is Part Of: Biomarkers in medicine. Volume 10:Number 7(2016)
• Page Start: 733
• Page End: 742
• Publication Date: 2016-07
• Subjects: chronic heart failure -- melanoma cell adhesion molecule -- prognosis; Biochemical markers -- Periodicals; 610.28
• DOI: 10.2217/bmm-2016-0053
• Languages: English
• ISSNs: 1752-0363

Abstract

Background: Melanoma cell adhesion molecule (MCAM) is a marker of endothelial damage. MCAM diagnostic and prognostic value was assessed in chronic heart failure (CHF).Materials & methods: 130 CHF patients and 32 controls were included in the study. Telephone follow-up lasted one year. End points were: death from all causes, and hospitalization with CHF exacerbation.Results: MCAM was higher in patients than in controls (p = 0.01). Receiver operator curve analysis revealed that MCAM may serve as a predictor of death (area under the curve: 0.8404; p < 0.002). Patients with MCAM above 500 ng/ml had worse prognosis (p = 0.03). NT-proBNP and age were independent predictors of death in multivariate analysis.Conclusion: The increased MCAM indicates endothelial damage in CHF and may serve as a marker of worse prognosis in these patients.